Adma Biologics, Inc. income statement

In fiscal 2025, Adma Biologics, Inc. reported revenue of $510m, up 19.6% on the year before, operating income of $191m (a 37.5% margin) and net income of $147m, or $0.60 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Adma Biologics, Inc.: income statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	1	1	3	6	7	11	23	17	29	42	81	154	258	426	510	512
Cost of revenue	—	—	—	—	—	2	29	42	40	61	80	119	169	207	217	181
Gross profit	1	0	1	2	3	4	−6	−25	−10	−19	1	35	89	220	293	331
Research and development	1	3	9	10	7	8	6	4	2	6	4	4	3	2	5	12
Selling, general and administrative	—	—	—	—	—	—	—	—	—	35	43	52	59	74	92	99
General and administrative	1	3	4	5	7	8	19	23	26	—	—	—	—	—	—	—
Operating income	−5	−8	−15	−16	−16	−17	−39	−60	−41	−65	−58	−39	22	139	191	224
Interest expense	2	0	1	1	2	2	3	6	9	12	13	19	25	14	7	9
Net interest income	−2	−0	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Income before tax	−6	−8	−16	−17	−18	−20	—	—	—	—	—	−66	−28	126	183	216
Income tax	—	−1	0	−1	0	0	0	0	0	0	0	0	0	−72	36	48
Net income	−6	−7	−16	−17	−18	−20	−44	−66	−48	−76	−72	−66	−28	198	147	169
Diluted EPS	−$0.28	−$0.35	−$0.59	−$0.45	−$0.43	−$0.40	−$0.95	−$1.45	−$0.89	−$0.88	−$0.51	−$0.33	−$0.13	$0.81	$0.60	$0.71
Diluted shares (average)	21m	21m	26m	37m	42m	49m	46m	45m	54m	86m	140m	198m	224m	243m	245m	239m
EBITDA	−4	−8	−15	−16	−15	−17	−38	−58	−39	−62	−54	−33	29	147	199	232

US$ millions unless shown otherwise. Fiscal quarters.

Adma Biologics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	120	118	115	122	134	139	114	124
Cost of revenue	60	54	54	55	59	50	34	38
Gross profit	60	63	61	67	76	89	81	86
Research and development	0	0	1	1	2	1	3	6
Selling, general and administrative	19	23	24	22	22	24	27	27
Operating income	40	38	35	43	51	63	58	52
Interest expense	3	3	2	2	2	2	2	3
Income before tax	37	35	33	40	48	62	57	50
Income tax	1	−77	7	6	11	12	12	12
Net income	36	112	27	34	36	49	45	38
Diluted EPS	$0.15	$0.46	$0.11	$0.14	$0.15	$0.20	$0.19	$0.16
EBITDA	42	40	37	45	53	65	60	54

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ADMA vs HCM ADMA vs KRYS ADMA vs ARQT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adma Biologics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Adma Biologics, Inc.